Amicus Therapeutics, Inc.
(NASDAQ : FOLD)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.66%164.280.7%$1339.46m
LLYEli Lilly & Co. 0.91%324.481.1%$1077.42m
ABBVAbbVie, Inc. 1.04%139.761.9%$861.13m
PFEPfizer Inc. 0.77%44.480.9%$804.31m
BMYBristol-Myers Squibb Co. 0.43%70.841.0%$776.06m
MRKMerck & Co., Inc. 0.11%87.650.7%$711.18m
AZNAstraZeneca Plc 1.67%56.481.0%$393.98m
ALNYAlnylam Pharmaceuticals, Inc. 0.55%197.888.2%$218.59m
GSKGSK Plc 1.70%30.770.3%$213.25m
NVSNovartis AG 1.37%77.720.2%$204.42m
GBTGlobal Blood Therapeutics, Inc. 0.00%68.485.4%$191.16m
IDXXIDEXX Laboratories, Inc. 3.00%346.793.9%$189.82m
ATXIAvenue Therapeutics, Inc. 31.71%15.160.0%$183.48m
HZNPHorizon Therapeutics Plc 2.14%65.645.4%$177.38m
SRPTSarepta Therapeutics, Inc. 1.13%111.1912.4%$138.29m

Company Profile

Amicus Therapeutics, Inc. operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Philadelphia, PA.